Last updated: September 3, 2026
Staurosporine is a broad-spectrum indolocarbazole kinase inhibitor used mainly as a biochemical research tool. It is not an FDA-approved drug, has no established commercial formulation, and has no identifiable late-stage clinical development program for the parent compound. Its principal pharmaceutical value has shifted to derivatives such as midostaurin, lestaurtinib, enzastaurin, and UCN-01, which were developed to improve selectivity, pharmacology, or clinical utility.
The direct market projection for staurosporine is therefore limited to laboratory research and specialty assay use. A conventional prescription-drug launch is unlikely without a major reformulation, a new clinical indication, and a differentiated safety profile.
What is staurosporine and how does it work?
Staurosporine is a microbial alkaloid originally isolated from Streptomyces staurosporeus. It inhibits protein kinases by competing at the ATP-binding site. Its activity extends across protein kinase C, cyclin-dependent kinases, Akt, receptor tyrosine kinases, and other kinase families, producing potent but poorly selective pharmacology (Omura et al., 1977; Tamaoki et al., 1986).
| Attribute |
Staurosporine |
| Chemical class |
Indolocarbazole alkaloid |
| Primary pharmacology |
Broad-spectrum ATP-competitive kinase inhibition |
| Common research use |
Apoptosis induction, kinase inhibition controls, assay calibration |
| Clinical status |
No approved drug |
| FDA status |
No FDA-approved application for staurosporine |
| Commercial dosage form |
No established marketed human dosage form |
| Main pharmaceutical descendants |
Midostaurin, lestaurtinib, UCN-01, enzastaurin |
| Principal development barrier |
Limited kinase selectivity and systemic toxicity |
Staurosporine also induces apoptosis through mechanisms that are not fully explained by kinase inhibition alone. Its broad target profile makes it useful for laboratory experiments but creates a narrow therapeutic window for systemic treatment.
What is the current development status of staurosporine?
The parent compound is not an active mainstream clinical development candidate. Public clinical development has focused on analogs rather than staurosporine itself.
Parent compound
Staurosporine has been evaluated in preclinical cancer models and cell-based studies. The compound is widely cited in laboratory protocols as a positive control for apoptosis and kinase inhibition. These uses do not establish a clinical development pathway.
No FDA approval, commercial human product, or recognized late-stage clinical program has been established for staurosporine. The compound does not have a standard oncology indication, recommended dose, or validated clinical biomarker strategy.
Key staurosporine derivatives
| Derivative |
Development outcome |
Current commercial status |
| Midostaurin |
Developed for FLT3-mutated acute myeloid leukemia and systemic mastocytosis |
FDA-approved as Rydapt |
| Lestaurtinib |
Studied in FLT3-mutated AML and other malignancies |
Not approved |
| UCN-01 |
Clinical studies in cancer, including leukemia and solid tumors |
Not approved |
| Enzastaurin |
Developed as a PKC-beta pathway inhibitor |
Not approved |
| K252 compounds |
Research and preclinical kinase inhibitors |
No established marketed human drug |
Midostaurin is the commercially successful branch of the staurosporine-derived class. Its approval does not establish regulatory or commercial momentum for staurosporine itself. Midostaurin has a substantially differentiated pharmacologic and clinical profile and is protected through its own development and formulation patent estate.
What is the FDA regulatory status of staurosporine?
Staurosporine has no FDA-approved label and no established Orange Book listing. The FDA Orange Book is limited to approved drug products and does not provide a standard listing for an unapproved research compound (U.S. Food and Drug Administration, 2024a).
No public FDA milestone supports a conventional regulatory timeline for the parent compound. There is no known:
- New Drug Application approval;
- approved prescription formulation;
- recognized pediatric exclusivity period;
- granted patent-term extension attached to an approved staurosporine product;
- Hatch-Waxman generic filing pathway;
- Orange Book-listed method-of-use patent.
This distinction is important. A company could develop a new staurosporine formulation or derivative under a new drug application, but that product would require independent clinical, manufacturing, safety, and intellectual-property support.
What patents protect staurosporine?
The original compound is an old natural product, and foundational disclosures are likely outside their enforceable patent terms in major jurisdictions. Patent protection for the parent molecule itself is therefore unlikely to provide a meaningful current exclusivity position.
The relevant patent opportunities would be narrower:
- New synthetic derivatives.
- Crystalline or amorphous forms.
- Injectable, oral, or targeted-delivery formulations.
- Combination therapies.
- Biomarker-defined treatment methods.
- Manufacturing processes with commercial advantages.
- Prodrugs that improve solubility, exposure, or tolerability.
A patent estate around a modern staurosporine program would likely protect a specific analog or formulation rather than the natural product broadly. The patent position for midostaurin illustrates this distinction. Patent rights associated with midostaurin do not automatically cover staurosporine, and staurosporine prior art may be used against novelty or obviousness arguments directed to related kinase inhibitors.
How many patents cover staurosporine?
There is no reliable basis for assigning a single global patent count to staurosporine. Patent databases contain records that may refer to the compound as a research reagent, a genus member, a kinase inhibitor, a derivative, or a combination agent. A raw keyword count would overstate enforceable coverage.
For commercial diligence, the relevant questions are:
| Patent issue |
Direct implication for staurosporine |
| Composition-of-matter patent |
Weak position for the old parent compound |
| New analog patent |
Potentially important if the analog has clinical differentiation |
| Formulation patent |
Could support exclusivity but requires a viable product |
| Method-of-use patent |
Could protect a biomarker-defined indication |
| Process patent |
May create manufacturing barriers but rarely supports broad market exclusivity |
| Orange Book listing |
None established for staurosporine |
| Patent-term extension |
None established for the parent compound |
| Paragraph IV exposure |
Not applicable without an approved listed drug |
A jurisdiction-specific freedom-to-operate opinion would need to separate expired foundational patents from live derivative, formulation, and process claims.
When does staurosporine lose exclusivity?
Staurosporine does not have a conventional U.S. regulatory exclusivity date because it has no approved product. The parent compound is effectively an off-patent research molecule unless a later patent claims a particular formulation, use, or derivative.
The relevant exclusivity timelines are different for products derived from the class:
| Product |
Active ingredient |
Regulatory status |
Exclusivity framework |
| Staurosporine |
Staurosporine |
Unapproved |
No FDA market exclusivity |
| Rydapt |
Midostaurin |
FDA-approved |
Product-specific patents and regulatory exclusivity |
| Lestaurtinib |
Lestaurtinib |
Unapproved |
No marketed-product exclusivity |
| UCN-01 |
UCN-01 |
Unapproved |
No marketed-product exclusivity |
A future staurosporine product could receive five years of new chemical entity exclusivity only if the FDA determined that the approved active moiety qualified as a new chemical entity. That outcome cannot be assumed for a previously characterized natural product or a derivative with prior regulatory history.
Are there Paragraph IV challenges or generic-entry risks?
There is no conventional Paragraph IV challenge against staurosporine because no FDA-approved staurosporine reference product is listed in the Orange Book.
Generic-entry risk is therefore not the central commercial issue. The more relevant risks are:
- development failure caused by nonspecific toxicity;
- inability to establish a therapeutic exposure window;
- competition from selective kinase inhibitors;
- inability to secure composition-of-matter claims;
- weak differentiation from existing apoptosis-inducing agents;
- manufacturing complexity for a structurally demanding natural product or analog.
If a sponsor developed and approved a new staurosporine formulation, later generic risk would depend on the approved formulation, listed patents, labeling, clinical exclusivity, and whether the product was treated as a new active moiety or a reformulation.
What patent litigation affects staurosporine?
No major public patent litigation has established market barriers around the parent compound. Litigation associated with staurosporine-derived drugs would generally concern the specific derivative, formulation, manufacturing method, or clinical use.
Midostaurin litigation and patent disputes, where applicable, should not be treated as direct staurosporine litigation. The products have different active ingredients, claims, regulatory approvals, and commercial strategies.
No established settlement agreement involving a generic entrant and an approved staurosporine product is apparent from the public regulatory framework. Paragraph IV settlements are generally tied to an approved reference product and Orange Book-listed patents, neither of which exists for staurosporine.
What formulations are protected or commercially viable?
Staurosporine has several development liabilities at the formulation level:
- limited aqueous solubility;
- broad intracellular target activity;
- narrow therapeutic margin;
- potential systemic toxicity;
- uncertain human pharmacokinetic profile;
- lack of a clinically validated dosing regimen.
Potential formulation strategies include liposomes, nanoparticles, polymeric delivery systems, antibody-directed conjugates, and localized administration. These approaches could reduce systemic exposure, but each would require new chemistry, manufacturing, and controls work. The resulting product would be a new drug-development program rather than a straightforward generic or reformulation opportunity.
A formulation patent could be commercially useful only if it produces measurable clinical advantages such as improved tumor exposure, lower toxicity, or a meaningful route-of-administration benefit.
How does staurosporine compare with midostaurin?
Midostaurin has a materially stronger commercial and regulatory position.
| Category |
Staurosporine |
Midostaurin |
| Selectivity |
Broad and nonspecific |
More clinically actionable kinase profile |
| FDA status |
Not approved |
Approved in AML and systemic mastocytosis |
| Clinical evidence |
Primarily preclinical or research use |
Established clinical development and labeling |
| Commercial product |
None |
Rydapt |
| Patent strategy |
Limited parent-compound value |
Product-specific composition, use, and formulation rights |
| Revenue model |
Research reagent market |
Specialty oncology medicine |
| Generic pathway |
No current reference product |
Potential future ANDA and patent challenges |
| Development risk |
Very high |
Established regulatory and clinical precedent |
Midostaurin demonstrates that a staurosporine-derived scaffold can support a commercial oncology product. It does not show that the parent compound has comparable development potential.
What is the market projection for staurosporine?
Direct staurosporine market
The direct market is likely to remain concentrated in research reagents, kinase assays, apoptosis studies, and academic or industrial screening. It is not a prescription pharmaceutical market.
A defensible commercial projection is:
| Market segment |
Five-year outlook |
| Research-grade staurosporine |
Stable niche demand |
| Clinical drug sales |
No credible launch base |
| Hospital use |
Minimal or none |
| Contract research use |
Moderate specialist demand |
| Staurosporine derivatives |
Separate and potentially substantial markets |
| Licensing value of parent compound |
Low unless linked to a novel platform |
No responsible revenue estimate can be assigned to a future prescription staurosporine product without an identified sponsor, development asset, indication, formulation, and clinical-stage program.
Investment view
Staurosporine alone has low pharmaceutical asset value. Its strongest commercial role is as:
- a validated kinase-inhibition scaffold;
- a source of medicinal-chemistry derivatives;
- a research control;
- a platform starting point for targeted delivery;
- prior art relevant to kinase inhibitor patent prosecution.
The opportunity is substantially stronger for a selective derivative with a defined biomarker population than for the parent molecule.
What are the principal generic, biosimilar, and competitive risks?
Biosimilar risk is not applicable because staurosporine is a small molecule, not a biologic. Generic risk is also inactive at present because no approved reference product exists.
Competitive risk is high. A clinical staurosporine program would compete with selective kinase inhibitors, apoptosis-targeting agents, antibody-drug conjugates, and molecularly defined oncology therapies. These competitors generally offer clearer target validation and more manageable regulatory positioning.
The main manufacturing barrier is the cost and complexity of producing a high-purity natural product or analog at clinical scale. That barrier may protect a supplier temporarily, but it does not create durable market exclusivity without patents, regulatory exclusivity, or a clinically differentiated product.
Key Takeaways
- Staurosporine is an unapproved, broad-spectrum kinase inhibitor used mainly as a research reagent.
- The parent compound has no established FDA approval, Orange Book listing, Paragraph IV exposure, or commercial human formulation.
- Foundational patent protection for the natural product is unlikely to provide meaningful current exclusivity.
- Commercial value resides primarily in derivatives, especially midostaurin, rather than in staurosporine itself.
- A viable development strategy would require improved selectivity, targeted delivery, a biomarker-defined indication, and new product-specific intellectual property.
- The direct pharmaceutical market projection is negligible relative to the markets for successful derivatives.
- Biosimilar risk does not apply; generic risk would arise only after approval of a new staurosporine product.
FAQs
Is staurosporine approved for cancer treatment?
No. Staurosporine is not an FDA-approved cancer treatment. It is mainly used in laboratory research.
Is staurosporine the same drug as midostaurin?
No. Midostaurin is a distinct staurosporine-derived molecule with its own clinical data, regulatory approval, patents, and commercial product, Rydapt.
Can staurosporine be repurposed as an apoptosis drug?
Potentially, but its broad kinase inhibition and toxicity concerns make systemic repurposing difficult. A successful program would likely require targeted delivery or a more selective derivative.
Does staurosporine have an Orange Book patent?
No established Orange Book listing exists for an approved staurosporine product. Orange Book patent analysis is more relevant to approved derivatives such as midostaurin.
Is staurosporine commercially available?
Research-grade staurosporine is commercially available from laboratory reagent suppliers. That availability does not indicate approval for human use or pharmaceutical manufacturing status.
References
-
Omura, S., Iwai, Y., Hirano, A., Nakagawa, A., Awaya, J., Tsuchiya, H., Takahashi, Y., & Asuma, R. (1977). A new alkaloid AM-2282 of Streptomyces origin. The Journal of Antibiotics, 30(4), 275-282.
-
Tamaoki, T., Nomoto, H., Takahashi, I., Kato, Y., Morimoto, M., & Tomita, F. (1986). Staurosporine, a potent inhibitor of phospholipid/Ca++ dependent protein kinase. Biochemical and Biophysical Research Communications, 135(2), 397-402.
-
U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (2024b). Rydapt (midostaurin) prescribing information. FDA.
-
National Center for Biotechnology Information. (2024). PubChem compound summary: Staurosporine. PubChem.
-
National Cancer Institute. (2024). Staurosporine. NCI Drug Dictionary.